Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 10Uveal Melanoma 3Multiple Myeloma 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1

Interventions

montanide ISA 51 2Interleukin-2 2binimetinib 1belinostat 1Vincristine 1Tramadol 1Topotecan 1Proton Therapy 1Peptides 1Melphalan 1Magnetic Resonance Spectroscopy 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Lasers 1Laparotomy 1Ibuprofen 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eye Enucleation 1Etoposide 1Doxorubicin 1D-methadone 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Eye Neoplasms × MAGEA3 protein, human × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡